pharmaceuticals

pharmaceuticals Articles

These are four top stocks to buy in a sector that has much more value than many on Wall Street. All are rated Buy at Jefferies and have outstanding upside potential.
The broad markets are inching forward on Wednesday after hitting new highs in what has been known as the Trump rally. Although the SPDR S&P Biotech ETF (NYSEMKT: XBI) is up about 1% on the day,...
Valeant Pharmaceuticals shares hit a multiyear low on Tuesday after it was announced that Bill Ackman would be selling off his stake in the company and stepping down from the board.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Valeant Pharmaceuticals announced that it intends to refinance some of its debt. One key analyst thinks that this might be a sign to abandon ship.
Markets may be slowing down and taking a step back after hitting new highs in what has been known as the Trump rally. Still, a few stocks in the health care sector were are absolutely screaming...
Merck and Pfizer each saw their shares sink early on Monday after the firms gave an update on their type 2 diabetes treatment.
Valeant Pharmaceuticals shares hit a multiyear low this past week, and some analysts took this opportunity to reevaluate their stance on the stock.
Here are three biotech companies that not only have data that could prove to be huge, but their shares have been absolutely hammered over the last year, offering aggressive accounts the best entry...
Opko Health and a few other biopharma companies made massive runs on Thursday.
These are some of the biggest biopharma stocks moving on Wednesday, as markets have hit new intraday highs, continuing to climb in the wake of the White House announcements.
Valeant Pharmaceuticals reported better-than-expected fourth-quarter financial results before the markets opened on Tuesday.
Judging by this report, short sellers are making a tremendous bet against Trump’s plan to reform the health care sector.
La Jolla Pharmaceutical saw its shares skyrocket on Monday after top-line results from its late-stage study of patients with catecholamine resistant hypotension.
The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the campaign trail. However things look like they could be different in 2017.